In fact, Clinical Trial Abundance and better hypotheses for drugs are not merely compatible, but self-reinforcing. Faster testing in the clinic creates a feedback loop: ideas become trials, trials generate rich data (including both successes and failures), these data improve models, and better models inform the next generation of ideas. In this view, the clinic is not an endpoint of discovery but a central component of it. To understand why clinical abundance is important, we must step outside the prevailing view of clinical testing as a mere “validation step” for scientific ideas. The familiar funnel metaphor of drug discovery, depicting a linear progression from basic science to regulatory approval, reinforces the flawed notion of clinical testing as a passive filter designed to screen pre-existing ideas. While this model is narrowly correct in a regulatory sense, it obscures the clinic’s role as an active engine of discovery.